Sugi Predict

Sugi Predict / Compounds / SCHEMBL898489

SCHEMBL898489

SCHEMBL898489

COc1ccc(-c2cc(C(=O)O)c(C(F)(F)F)o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.52
▸ KDM4E B2RXH2 4/20 0.52
▸ NR4A2 P43354 1/20 0.50
▸ ALDH1A1 P00352 7/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ HTT P42858 2/20 0.49
▸ PKM P14618 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HPGD P15428 3/20 0.49
▸ RECQL P46063 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ EGFR P00533 1/20 0.49
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA3 P07451 1/20 0.47
▸ CA4 P22748 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA7 P43166 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31223798 0.85 ALDH1A1 (0.52) MAPTKDM4EALDH1A1HSD17B10HTT
SCHEMBL28630542 0.85 ALDH1A1 (0.52) MAPTKDM4EALDH1A1HSD17B10HTT
SCHEMBL5860864 0.82 FFAR1 (0.46) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL14050010 0.82 ALDH1A1 (0.51) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL595184 0.82 ALDH1A1 (0.54) KDM4EALDH1A1HSD17B10HTTPKM
SCHEMBL2063655 0.81 NPC1 (0.61) MAPTKDM4EALDH1A1HTTPKM
SCHEMBL897655 0.81 PTPN1 (0.45) MAPTKDM4EALDH1A1HSD17B10PKM
SCHEMBL14930776 0.80 P2RX1 (0.61) MAPTKDM4EALDH1A1HPGD
SCHEMBL3973924 0.80 ALDH1A1 (0.69) MAPTKDM4ENR4A2ALDH1A1HSD17B10
SCHEMBL3972861 0.79 MAPT (0.57) MAPTKDM4EALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2576532-B1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX LLC (US) 2018-07-18 — — EP disclosed
US-9663483-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2017-05-30 — — US disclosed
US-20160024040-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC 2016-01-28 — — US disclosed
US-9149527-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2015-10-06 — — US disclosed
US-20140309297-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2014-10-16 — — US disclosed
US-8722731-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2014-05-13 — — US disclosed
US-20130116317-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2013-05-09 — — US disclosed
EP-2576532-A1 FURANYL COMPOUNDS AND THE USE THEREOF Novomedix, LLC (US) 2013-04-10 — — EP disclosed
WO-2011156321-A9 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2012-04-05 — — WO disclosed
WO-2011156321-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2011-12-15 — — WO disclosed
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2008-12-11 — — US disclosed
US-7417068-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-08-26 — — US disclosed
US-7417068-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-08-26 — — US disclosed
US-7417068-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-08-26 — — US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 — — US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 — — US disclosed
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2007-06-14 — — US disclosed
EP-1673360-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2006-06-28 — — EP disclosed
US-20050124676-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2005-06-09 — — US disclosed
WO-2005037812-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2005-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116317-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, EIF4A1 MAPT 4064/4885KDM4E 423/4885NR4A2 2444/4885
US-20050124676-A1 EP4 receptor antagonists PTGER4, PTGER3, NR4A3 MAPT 4666/4885KDM4E 2329/4885NR4A2 8/4885
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER3, NR4A3 MAPT 4666/4885KDM4E 2329/4885NR4A2 8/4885
US-20070135503-A1 Furan derivatives as ep4 receptor antagonists PTGER4, PTGER3, NR4A3 MAPT 4720/4885KDM4E 2558/4885NR4A2 7/4885
US-20160024040-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, GLI1 MAPT 3803/4885KDM4E 369/4885NR4A2 2499/4885
US-20140309297-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, GLI1 MAPT 3803/4885KDM4E 369/4885NR4A2 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.